Cara Therapeutics, Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

CR845 · Dermatology / Nephrology
CR845 is a selective kinin B1 receptor antagonist that blocks inflammatory signaling to reduce pruritus and other inflammatory symptoms.

Phase 1 pipeline

[14C] CR845

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: